Safe Prescribing — MCQs
On this page
A 48-year-old man with type 2 diabetes attends the emergency department following an episode of severe hypoglycaemia at home where paramedics administered intramuscular glucagon. He is currently conscious with blood glucose 7.8 mmol/L after receiving oral glucose. His regular medications include insulin glargine 54 units at bedtime, insulin aspart 16 units with meals, metformin 1g twice daily, and ramipril 10mg daily. He reports missing his evening meal but taking his usual insulin doses. What is the most important immediate advice regarding his diabetes management for the next 24 hours?
A 56-year-old woman with deep vein thrombosis is on day 12 of rivaroxaban treatment. She was initiated on rivaroxaban 15mg twice daily for 21 days as per protocol. She asks when her dose will be changed. According to current UK licensing and guidelines, when should her rivaroxaban dose be changed and to what dose?
A 61-year-old man with type 1 diabetes for 28 years is admitted with a foot ulcer and cellulitis. He is commenced on intravenous antibiotics. His usual insulin regimen is insulin glargine 28 units at 22:00 and insulin lispro 10 units before each meal. He is eating normally. His blood glucose on admission is 16.8 mmol/L and ketones are 0.8 mmol/L. What is the most appropriate insulin management for this patient during his admission?
A 52-year-old man with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. He reports three episodes of nocturnal hypoglycaemia over the past week, with blood glucose readings of 2.8, 3.1, and 2.6 mmol/L at approximately 3am. His fasting glucose readings range from 9.2 to 11.4 mmol/L. What is the most appropriate next step in his insulin management?
A 67-year-old man with mechanical aortic valve replacement is on warfarin with target INR 2.5-3.5. He presents to the emergency department with epistaxis that has been ongoing for 45 minutes and is haemodynamically stable. His INR is 8.2 and haemoglobin is 125 g/L. He is not actively bleeding at the time of assessment. What is the most appropriate immediate management of his elevated INR?
A 38-year-old woman with type 2 diabetes is 8 weeks pregnant. She has been managed on metformin 1g twice daily and insulin detemir 18 units at bedtime for the past year with good glycaemic control (HbA1c 48 mmol/mol). She attends antenatal clinic for review. What is the most appropriate modification to her diabetes management in pregnancy?
A 71-year-old man with atrial fibrillation is established on rivaroxaban 20mg once daily. He is admitted with acute limb ischaemia requiring emergency embolectomy within 2 hours. His most recent dose of rivaroxaban was taken 8 hours ago. He is haemodynamically stable. Which of the following is the most appropriate immediate management of his anticoagulation prior to surgery?
A 45-year-old woman with type 1 diabetes is admitted with suspected acute pancreatitis. Her current insulin regimen includes insulin glargine 24 units at bedtime and insulin aspart 8 units with meals. She is made nil by mouth and commenced on intravenous fluids. Her admission blood glucose is 14.2 mmol/L. What is the most appropriate insulin management strategy for this patient?
A 54-year-old woman with rheumatoid arthritis is started on methotrexate 7.5mg weekly. She asks about important safety information regarding her new medication. According to current UK prescribing guidance, which of the following is the most appropriate advice regarding methotrexate administration?
A 74-year-old woman with atrial fibrillation has been on apixaban 5mg twice daily for 2 years. She now requires long-term rifampicin therapy for Mycobacterium avium complex infection. Her renal function is normal (eGFR 68 ml/min/1.73m²), weight 72kg, and she has no other significant medications. What is the most appropriate anticoagulation management during rifampicin treatment?
Safe Prescribing UK Medical PG Practice Questions and MCQs
Question 31: A 48-year-old man with type 2 diabetes attends the emergency department following an episode of severe hypoglycaemia at home where paramedics administered intramuscular glucagon. He is currently conscious with blood glucose 7.8 mmol/L after receiving oral glucose. His regular medications include insulin glargine 54 units at bedtime, insulin aspart 16 units with meals, metformin 1g twice daily, and ramipril 10mg daily. He reports missing his evening meal but taking his usual insulin doses. What is the most important immediate advice regarding his diabetes management for the next 24 hours?
- A. Discontinue metformin for 48 hours as it may have contributed to hypoglycaemia
- B. Reduce all insulin doses by 20% and ensure regular carbohydrate intake with frequent monitoring (Correct Answer)
- C. Continue usual insulin regimen but ensure adequate carbohydrate intake with each dose
- D. Omit evening basal insulin dose and restart tomorrow morning
- E. Switch from insulin aspart to regular soluble insulin for better glycaemic stability
Explanation: ***Reduce all insulin doses by 20% and ensure regular carbohydrate intake with frequent monitoring*** - Following a severe hypoglycaemic episode, especially requiring **glucagon**, the body's **glycogen stores** are significantly depleted, increasing the risk of **recurrent hypoglycaemia** within the next 24-48 hours. - A **20% reduction** in both basal (glargine) and bolus (aspart) insulin doses, coupled with frequent monitoring and regular carbohydrate intake, provides a crucial safety margin to prevent further severe events. *Discontinue metformin for 48 hours as it may have contributed to hypoglycaemia* - **Metformin** primarily works by decreasing hepatic glucose production and improving insulin sensitivity; it has a very low risk of causing **hypoglycaemia** when used alone or in combination with insulin, especially when compared to insulin itself. - Discontinuing metformin would not address the immediate risk of further hypoglycaemia, which is primarily due to the insulin doses relative to carbohydrate intake. *Continue usual insulin regimen but ensure adequate carbohydrate intake with each dose* - Continuing the usual insulin doses after a severe hypoglycaemic event is **unsafe** because the patient's body has already demonstrated an inability to cope with this regimen in the context of a missed meal, and **counter-regulatory responses** may be blunted. - Relying solely on increased carbohydrate intake without insulin adjustment is risky and does not account for potential variations in meal timing, digestion, or absorption. *Omit evening basal insulin dose and restart tomorrow morning* - Completely omitting the evening **basal insulin (glargine)** dose can lead to significant and potentially dangerous **hyperglycaemia** overnight and into the next morning, increasing the risk of **ketosis** in some individuals with type 2 diabetes. - A dose reduction is a safer approach, maintaining some background insulin activity while mitigating the risk of further hypoglycaemia. *Switch from insulin aspart to regular soluble insulin for better glycaemic stability* - Switching insulin types in an acute setting following severe hypoglycaemia is generally not recommended as it introduces new variables and potential for **medication errors**. - **Regular soluble insulin** has a slower onset and longer peak action compared to rapid-acting insulin aspart, which could lead to suboptimal post-meal glucose control or an increased risk of **delayed hypoglycaemia**.
Question 32: A 56-year-old woman with deep vein thrombosis is on day 12 of rivaroxaban treatment. She was initiated on rivaroxaban 15mg twice daily for 21 days as per protocol. She asks when her dose will be changed. According to current UK licensing and guidelines, when should her rivaroxaban dose be changed and to what dose?
- A. Continue 15mg twice daily for total of 21 days, then switch to 20mg once daily (Correct Answer)
- B. Switch immediately to 20mg once daily as therapeutic levels have been achieved
- C. Continue 15mg twice daily for total of 21 days, then switch to 15mg once daily
- D. Continue 15mg twice daily for 6 weeks, then switch to 20mg once daily
- E. Switch to 10mg twice daily after 21 days for long-term maintenance
Explanation: ***Continue 15mg twice daily for total of 21 days, then switch to 20mg once daily*** - According to **NICE guidelines** and UK licensing for **DVT or PE treatment**, **rivaroxaban** initiation involves a loading dose of **15mg twice daily** for the first **21 days** to ensure rapid and effective anticoagulation. - After this intensive loading phase, the dose is reduced to **20mg once daily** for ongoing maintenance therapy, which is crucial for preventing recurrent **venous thromboembolism**. *Switch immediately to 20mg once daily as therapeutic levels have been achieved* - Switching to a lower total daily dose before completing the **21-day loading phase** would result in sub-therapeutic anticoagulation during the critical acute period, increasing the risk of **thrombus propagation**. - The twice-daily **15mg rivaroxaban** regimen for the initial 21 days is specifically designed to achieve optimal therapeutic levels quickly and intensely for acute treatment. *Continue 15mg twice daily for total of 21 days, then switch to 15mg once daily* - The **15mg once daily** dose of rivaroxaban is typically reserved for patients with **moderate renal impairment** (creatinine clearance 15-49 ml/min) during the maintenance phase, not as a standard dose for all patients after the loading period. - For patients with normal renal function, the standard maintenance dose after the initial 21 days is **20mg once daily**, as per UK guidelines. *Continue 15mg twice daily for 6 weeks, then switch to 20mg once daily* - Extending the intensive **15mg twice daily** regimen beyond **21 days** (3 weeks) to 6 weeks is not in line with current UK licensing or **NICE guidelines** for the acute treatment of DVT/PE. - This prolonged high-dose therapy would unnecessarily increase the risk of **bleeding complications** without providing additional clinical benefit for most patients. *Switch to 10mg twice daily after 21 days for long-term maintenance* - A **10mg twice daily** regimen for rivaroxaban is not a recognized or licensed dose for the maintenance treatment of **DVT or PE** in the UK. - While a **10mg once daily** dose may be considered for extended prevention of recurrent VTE after at least 6 months of initial treatment, it is not the standard immediate maintenance dose after the 21-day loading phase.
Question 33: A 61-year-old man with type 1 diabetes for 28 years is admitted with a foot ulcer and cellulitis. He is commenced on intravenous antibiotics. His usual insulin regimen is insulin glargine 28 units at 22:00 and insulin lispro 10 units before each meal. He is eating normally. His blood glucose on admission is 16.8 mmol/L and ketones are 0.8 mmol/L. What is the most appropriate insulin management for this patient during his admission?
- A. Continue subcutaneous basal-bolus insulin regimen and increase monitoring frequency (Correct Answer)
- B. Discontinue subcutaneous insulin and commence variable rate intravenous insulin infusion
- C. Continue insulin glargine and commence variable rate intravenous insulin infusion
- D. Increase insulin glargine to 34 units and insulin lispro to 14 units for all meals
- E. Switch to subcutaneous fixed-rate soluble insulin 6-hourly regimen
Explanation: ***Continue subcutaneous basal-bolus insulin regimen and increase monitoring frequency***- For patients with **type 1 diabetes** who are **eating and drinking normally**, the preferred management is to continue their established **basal-bolus regimen** and monitor closely for illness-related fluctuations.- While the blood glucose is elevated (16.8 mmol/L), the **ketones (0.8 mmol/L)** are below the threshold for **Diabetic Ketoacidosis (DKA)**, meaning a transition to intravenous insulin is not immediately required. *Discontinue subcutaneous insulin and commence variable rate intravenous insulin infusion*- **Variable Rate Intravenous Insulin Infusion (VRIII)** is generally reserved for patients who are **nil by mouth (NBM)**, those with **severe DKA/HHS**, or undergoing surgery.- The patient is **eating normally**, making VRIII inappropriate and increasing the risk of **iatrogenic hypoglycemia** and requiring intensive nursing supervision. *Continue insulin glargine and commence variable rate intravenous insulin infusion*- This combined approach (basal insulin plus VRIII) is typically used for NBM patients to provide basal coverage or during the transition from VRIII to subcutaneous insulin, but it is **not indicated** for a patient actively eating.- Since the patient is stable and consuming meals, **subcutaneous boluses** for meals are essential, and a continuous IV infusion is an **overkill** given the current ketone levels. *Increase insulin glargine to 34 units and insulin lispro to 14 units for all meals*- While infection and cellulitis increase **insulin resistance**, a large, **preemptive increase** in all doses carries a high risk of **hypoglycemia** once the infection begins to clear or the patient's condition improves.- Dose adjustments should be made **incrementally** based on **frequent blood glucose monitoring** (at least every 2-4 hours) and correctional scales, rather than a radical change at admission. *Switch to subcutaneous fixed-rate soluble insulin 6-hourly regimen*- Switching to a **fixed-rate soluble insulin** regimen is less physiological and flexible than the patient's existing **basal-bolus** routine, making glycemic control more difficult, especially in the context of fluctuating needs during illness.- Maintaining the patient's **insulin glargine** (long-acting basal insulin) provides better background stability compared to 6-hourly short-acting doses, which can lead to periods of **insulin stacking** or inadequate coverage.
Question 34: A 52-year-old man with type 2 diabetes is established on insulin glargine 42 units at bedtime and metformin 1g twice daily. He reports three episodes of nocturnal hypoglycaemia over the past week, with blood glucose readings of 2.8, 3.1, and 2.6 mmol/L at approximately 3am. His fasting glucose readings range from 9.2 to 11.4 mmol/L. What is the most appropriate next step in his insulin management?
- A. Reduce insulin glargine dose by 10-20% and monitor blood glucose patterns
- B. Switch insulin glargine from bedtime to morning administration (Correct Answer)
- C. Add insulin aspart 4 units with evening meal and reduce glargine to 30 units
- D. Increase insulin glargine to 48 units and advise bedtime snack
- E. Continue current dose and ensure adequate carbohydrate intake before bed
Explanation: ***Switch insulin glargine from bedtime to morning administration*** - This patient exhibits a pattern of recurrent **nocturnal hypoglycemia** (2.6-3.1 mmol/L around 3 AM) followed by **rebound morning hyperglycemia** (9.2-11.4 mmol/L), characteristic of the **Somogyi effect**. - Moving the dose of **long-acting basal insulin (glargine)** to the morning helps shift its peak activity away from the vulnerable early morning hours, reducing the risk of hypoglycemia while maintaining overall 24-hour glycemic control. *Reduce insulin glargine dose by 10-20% and monitor blood glucose patterns* - While reducing the dose might mitigate nocturnal hypoglycemia, it would likely worsen the patient's already high **fasting glucose readings**, indicating insufficient basal insulin effect during the day. - This approach fails to address the underlying issue of **insulin timing** contributing to the Somogyi effect and could lead to poorer overall glycemic control. *Add insulin aspart 4 units with evening meal and reduce glargine to 30 units* - Adding **rapid-acting insulin (aspart)** with the evening meal could exacerbate early nocturnal hypoglycemia due to its peak action occurring within a few hours of injection. - This modification introduces unnecessary complexity and does not directly resolve the problem of inappropriately timed **basal insulin**, which is causing the 3 AM drops. *Increase insulin glargine to 48 units and advise bedtime snack* - Increasing the **insulin glargine dose** is contraindicated as it would significantly worsen the frequency and severity of the existing **nocturnal hypoglycaemia**. - Relying on a **bedtime snack** is a temporary measure and does not address the fundamental issue of the inappropriate timing of basal insulin, which is precipitating the recurrent lows. *Continue current dose and ensure adequate carbohydrate intake before bed* - Continuing the current regimen will perpetuate the cycle of **nocturnal hypoglycaemia** and subsequent **rebound hyperglycaemia**, leaving the patient at continued risk. - While ensuring adequate carbohydrate intake before bed can temporarily raise blood glucose, it is a reactive measure and does not resolve the fundamental problem with the **basal insulin's timing** that is causing the recurrent nocturnal drops.
Question 35: A 67-year-old man with mechanical aortic valve replacement is on warfarin with target INR 2.5-3.5. He presents to the emergency department with epistaxis that has been ongoing for 45 minutes and is haemodynamically stable. His INR is 8.2 and haemoglobin is 125 g/L. He is not actively bleeding at the time of assessment. What is the most appropriate immediate management of his elevated INR?
- A. Administer vitamin K 5mg intravenously and withhold warfarin
- B. Administer four-factor prothrombin complex concentrate and vitamin K 5mg intravenously
- C. Administer vitamin K 1-3mg orally and withhold warfarin (Correct Answer)
- D. Withhold warfarin and recheck INR in 24 hours without vitamin K administration
- E. Administer fresh frozen plasma and vitamin K 10mg intravenously
Explanation: ***Administer vitamin K 1-3mg orally and withhold warfarin***- This patient presents with an **elevated INR (8.2)** and experienced **minor bleeding (epistaxis)**, but is now **haemodynamically stable** and not actively bleeding, making this the most appropriate approach.- For an INR between 4.5-10.0 with minor or no bleeding, guidelines recommend **withholding warfarin** and administering a **low dose of oral Vitamin K (1-2.5 mg)** to safely reduce the INR without causing over-reversal or warfarin resistance, which is vital for a patient with a **mechanical aortic valve**.*Administer vitamin K 5mg intravenously and withhold warfarin*- **Intravenous Vitamin K** is generally reserved for patients with **major bleeding** or those unable to take oral medication; neither applies here as his bleeding is minor and stopped.- A 5mg IV dose is relatively high for minor bleeding and risks rapid, excessive INR reduction, which can lead to **warfarin resistance** and increased **thromboembolic risk** for his prosthetic valve when warfarin is restarted.*Administer four-factor prothrombin complex concentrate and vitamin K 5mg intravenously*- **Four-factor prothrombin complex concentrate (PCC)** is indicated for urgent warfarin reversal in cases of **major or life-threatening bleeding** or before emergency surgery.- Since the patient is **haemodynamically stable** and not actively bleeding, aggressive reversal with PCC is unnecessary and carries a significant risk of **thrombosis**.*Withhold warfarin and recheck INR in 24 hours without vitamin K administration*- Simply withholding warfarin without Vitamin K is typically for **asymptomatic patients** with an INR between **5.0 and 8.0** without any bleeding.- Because this patient presented with **minor bleeding** and his INR is > 8.0, **Vitamin K administration** is necessary to more promptly and safely reduce the INR and mitigate further hemorrhage risk.*Administer fresh frozen plasma and vitamin K 10mg intravenously*- **Fresh frozen plasma (FFP)** is less effective than PCC for immediate warfarin reversal due to its volume and slower infusion time, and it is not indicated for stable patients with minor bleeding.- A **10mg IV dose of Vitamin K** is a high dose reserved for **severe, life-threatening hemorrhage**, which is not the clinical scenario here.
Question 36: A 38-year-old woman with type 2 diabetes is 8 weeks pregnant. She has been managed on metformin 1g twice daily and insulin detemir 18 units at bedtime for the past year with good glycaemic control (HbA1c 48 mmol/mol). She attends antenatal clinic for review. What is the most appropriate modification to her diabetes management in pregnancy?
- A. Switch insulin detemir to insulin glargine as it has better pregnancy data
- B. Switch insulin detemir to insulin aspart for better fetal safety profile
- C. Continue insulin detemir and increase blood glucose monitoring frequency (Correct Answer)
- D. Discontinue insulin detemir and increase metformin to 1.5g twice daily
- E. Continue current regimen unchanged as glycaemic control is good
Explanation: ***Continue insulin detemir and increase blood glucose monitoring frequency***- **Insulin detemir** is a **long-acting insulin analog** considered safe and effective in pregnancy, with extensive data supporting its use. Continuing an established regimen is appropriate if control is good.- **Increased blood glucose monitoring** (e.g., fasting and 1-hour postprandial) is critical to meet **stricter glycaemic targets** during pregnancy, which are essential for minimizing maternal and fetal complications.*Continue current regimen unchanged as glycaemic control is good*- While pre-pregnancy control was good, **glycaemic targets become stricter** in pregnancy to prevent adverse outcomes, necessitating more intensive monitoring.- Physiological changes, including increasing **insulin resistance** in later trimesters, often require dose adjustments even if the initial regimen was effective.*Switch insulin detemir to insulin glargine as it has better pregnancy data*- Both **insulin detemir** and **insulin glargine** (U100) have robust safety profiles and are recommended basal insulins in pregnancy, so there is no clinical advantage in switching from one to the other.- Switching a well-controlled patient from one safe insulin to another without a clear indication can disrupt **stable glycaemic control**.*Switch insulin detemir to insulin aspart for better fetal safety profile*- **Insulin detemir** is a **basal (long-acting) insulin**, whereas **insulin aspart** is a **prandial (rapid-acting) insulin**; they serve different purposes and are not interchangeable.- Switching would eliminate **basal glucose control**, leading to hyperglycemia between meals and overnight, despite aspart being safe for prandial use in pregnancy.*Discontinue insulin detemir and increase metformin to 1.5g twice daily*- Discontinuing insulin in a patient who requires it for good control, especially in pregnancy when **insulin requirements increase**, would almost certainly lead to **hyperglycemia**.- While **metformin** can be continued, increasing its dose alone is unlikely to compensate for the complete withdrawal of basal insulin, risking poor glycaemic control and fetal complications like **macrosomia**.
Question 37: A 71-year-old man with atrial fibrillation is established on rivaroxaban 20mg once daily. He is admitted with acute limb ischaemia requiring emergency embolectomy within 2 hours. His most recent dose of rivaroxaban was taken 8 hours ago. He is haemodynamically stable. Which of the following is the most appropriate immediate management of his anticoagulation prior to surgery?
- A. Administer protamine sulphate 50mg intravenously and proceed to surgery
- B. Administer andexanet alfa and proceed to surgery
- C. Administer vitamin K 10mg intravenously and delay surgery for 6 hours
- D. Administer four-factor prothrombin complex concentrate and proceed to surgery
- E. Proceed to surgery without reversal agent; use standard haemostatic measures (Correct Answer)
Explanation: ***Proceed to surgery without reversal agent; use standard haemostatic measures***- In **acute limb ischaemia**, time to revascularization is critical for limb viability, and the patient is currently **haemodynamically stable**, allowing for surgery with meticulous technique.- **Rivaroxaban** has a relatively short half-life (5-9 hours), and since the last dose was 8 hours ago, anticoagulant activity is already naturally declining.*Administer protamine sulphate 50mg intravenously and proceed to surgery*- **Protamine sulphate** is the specific reversal agent for **unfractionated heparin** and has no effect on Factor Xa inhibitors like rivaroxaban.- Using it in this context would be ineffective and provide a false sense of security regarding the patient's bleeding risk.*Administer andexanet alfa and proceed to surgery*- **Andexanet alfa** is typically reserved for **life-threatening or uncontrolled bleeding** (e.g., intracranial hemorrhage) rather than preoperative management in a stable patient.- Its use is limited by high cost and restricted availability in many surgical centers for non-hemorrhagic indications.*Administer vitamin K 10mg intravenously and delay surgery for 6 hours*- **Vitamin K** is used specifically to reverse the effects of **warfarin** by facilitating the synthesis of clotting factors; it does not affect DOACs like rivaroxaban.- Delaying surgery for 6 hours in a case of **acute limb ischaemia** unnecessarily increases the risk of irreversible tissue necrosis and limb loss.*Administer four-factor prothrombin complex concentrate and proceed to surgery*- **Four-factor PCC** is used off-label for Factor Xa inhibitor reversal primarily when **andexanet alfa** is unavailable or when there is active, severe bleeding.- In the absence of active bleeding or a high-risk life-threatening scenario, the **thrombotic risk** of PCC must be weighed against its questionable benefit for prophylactic surgical reversal.
Question 38: A 45-year-old woman with type 1 diabetes is admitted with suspected acute pancreatitis. Her current insulin regimen includes insulin glargine 24 units at bedtime and insulin aspart 8 units with meals. She is made nil by mouth and commenced on intravenous fluids. Her admission blood glucose is 14.2 mmol/L. What is the most appropriate insulin management strategy for this patient?
- A. Continue subcutaneous basal-bolus insulin unchanged and monitor blood glucose 4-hourly
- B. Switch to subcutaneous insulin detemir twice daily and discontinue prandial insulin
- C. Discontinue all insulin and commence variable rate intravenous insulin infusion with glucose monitoring
- D. Continue subcutaneous insulin glargine and commence variable rate intravenous insulin infusion (Correct Answer)
- E. Discontinue all insulin temporarily and restart only when oral intake recommences
Explanation: ***Continue subcutaneous insulin glargine and commence variable rate intravenous insulin infusion***- In **Type 1 diabetes**, patients have an absolute insulin deficiency and always require a **basal insulin** (like glargine) to prevent the development of **diabetic ketoacidosis (DKA)**.- When a patient is **nil by mouth**, a **Variable Rate Intravenous Insulin Infusion (VRIII)** replaces mealtime boluses to maintain glycemic control while the background basal insulin provides stable metabolic coverage.*Continue subcutaneous basal-bolus insulin unchanged and monitor blood glucose 4-hourly*- Continuing **prandial (bolus) insulin** while the patient is not eating significantly increases the risk of severe **hypoglycemia**.- Monitoring every 4 hours is insufficient for a patient with an **acute illness** like pancreatitis who is not receiving oral nutrition.*Switch to subcutaneous insulin detemir twice daily and discontinue prandial insulin*- Switching basal insulin types during an acute admission is unnecessary and can cause **dosing errors** or metabolic instability.- Discontinuing prandial insulin without replacing it with a **VRIII** will result in poor glycemic control (hyperglycemia) due to the **stress response** of acute pancreatitis.*Discontinue all insulin and commence variable rate intravenous insulin infusion with glucose monitoring*- Discontinuing long-acting basal insulin makes the transition off the VRIII more difficult and increases the risk of **rebound hyperglycemia** or DKA if the infusion is interrupted.- Guidelines recommend continuing **basal subcutaneous insulin** alongside VRIII to provide a safety net and simplify the return to a standard regimen.*Discontinue all insulin temporarily and restart only when oral intake recommences*- This is a dangerous strategy in **Type 1 diabetes** as it will inevitably lead to **diabetic ketoacidosis** within hours due to the complete lack of circulating insulin.- Patients with Type 1 diabetes always require **endogenous or exogenous insulin** to suppress ketogenesis, regardless of their nutritional status.
Question 39: A 54-year-old woman with rheumatoid arthritis is started on methotrexate 7.5mg weekly. She asks about important safety information regarding her new medication. According to current UK prescribing guidance, which of the following is the most appropriate advice regarding methotrexate administration?
- A. Take the medication daily with food to reduce gastrointestinal side effects
- B. Take the medication once weekly on the same day each week (Correct Answer)
- C. Take the medication twice daily, morning and evening, for optimal efficacy
- D. Take the medication every other day to maintain steady therapeutic levels
- E. Take the medication three times weekly on alternate days
Explanation: ***Take the medication once weekly on the same day each week***- In the treatment of inflammatory conditions like **rheumatoid arthritis**, methotrexate must be taken as a **once-weekly dose** to prevent severe toxicity and potential fatality.- To enhance safety, patients should consistently choose the **same day each week** and clear "ONCE WEEKLY" instructions must be included on the prescription and packaging.*Take the medication daily with food to reduce gastrointestinal side effects*- Daily administration of methotrexate is typically reserved for **oncology protocols** and is inappropriate for rheumatological conditions.- Prescribing methotrexate daily instead of weekly is a high-risk **medication error** that can lead to life-threatening **bone marrow suppression** and mucositis.*Take the medication twice daily, morning and evening, for optimal efficacy*- Multi-dose daily regimens are not used for rheumatoid arthritis and significantly increase the risk of acute **methotrexate toxicity**.- Guidance emphasizes that **splitting doses** within a single day is generally discouraged in primary care to avoid confusion with daily dosing.*Take the medication every other day to maintain steady therapeutic levels*- **Alternate-day dosing** is not a recognized regimen for methotrexate in this clinical context and would result in an accumulated overdose.- Maintaining "steady levels" through frequent dosing leads to the inhibition of folate metabolism in healthy cells, causing **organ failure**.*Take the medication three times weekly on alternate days*- This frequency is incorrect and deviates from the **NICE and MHRA safety guidelines** which mandate strictly weekly administration.- Safety warnings often highlight that any frequency more often than **once weekly** in rheumatology is a major prescribing hazard.
Question 40: A 74-year-old woman with atrial fibrillation has been on apixaban 5mg twice daily for 2 years. She now requires long-term rifampicin therapy for Mycobacterium avium complex infection. Her renal function is normal (eGFR 68 ml/min/1.73m²), weight 72kg, and she has no other significant medications. What is the most appropriate anticoagulation management during rifampicin treatment?
- A. Continue apixaban 5mg twice daily as rifampicin does not affect apixaban levels significantly
- B. Increase apixaban to 7.5mg twice daily to compensate for increased metabolism
- C. Switch to warfarin and monitor INR closely, adjusting dose to maintain therapeutic range (Correct Answer)
- D. Switch to rivaroxaban 20mg once daily as it is less affected by rifampicin than apixaban
- E. Increase apixaban to 10mg twice daily during rifampicin therapy
Explanation: ***Switch to warfarin and monitor INR closely, adjusting dose to maintain therapeutic range***- **Rifampicin** is a potent inducer of **CYP3A4** and **P-glycoprotein**, which significantly reduces the plasma concentration of **DOACs** like apixaban, increasing stroke risk.- Unlike DOACs, **warfarin** allows for titration through **INR monitoring**, ensuring that the increased metabolic clearance caused by rifampicin is compensated for by dose adjustments.*Continue apixaban 5mg twice daily as rifampicin does not affect apixaban levels significantly*- This approach is dangerous because rifampicin can reduce **apixaban levels** by more than 50%, leaving the patient inadequately protected against **thromboembolism**.- Co-administration of strong **CYP3A4 inducers** with DOACs is generally contraindicated in current clinical guidelines due to unpredictable efficacy.*Increase apixaban to 7.5mg twice daily to compensate for increased metabolism*- There is no clinical evidence or established safety data to support **off-label dose escalation** of apixaban to override drug interactions.- 7.5mg is not a standard manufactured dose, and standard dosing cannot be reliably monitored for efficacy in the same way as **warfarin**.*Switch to rivaroxaban 20mg once daily as it is less affected by rifampicin than apixaban*- **Rivaroxaban** is also a substrate of **CYP3A4** and **P-gp**, meaning its levels are similarly depleted by rifampicin induction.- Using another DOAC does not solve the underlying problem of **unquantifiable drug levels** and high risk of anticoagulant failure.*Increase apixaban to 10mg twice daily during rifampicin therapy*- Doubling the dose to **10mg twice daily** lacks pharmacokinetic validation and increases the risk of unpredictable toxicity once rifampicin is eventually discontinued.- Monitoring **Factor Xa levels** is not widely available or standardized enough to safely manage such a high-dose regimen in primary or secondary care.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free